Loss of E-cadherin-dependent cell–cell adhesion and the development and progression of cancer
HC Bruner, PWB Derksen - Cold Spring Harbor …, 2018 - cshperspectives.cshlp.org
Classical cadherins are the key molecules that control cell–cell adhesion. Notwithstanding
this function, it is also clear that classical cadherins are more than just the “glue” that keeps …
this function, it is also clear that classical cadherins are more than just the “glue” that keeps …
Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy
Abstract Invasive lobular carcinoma comprises 10–15% of all breast cancers and is
increasingly recognised as a distinct and understudied disease compared with the …
increasingly recognised as a distinct and understudied disease compared with the …
E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer
I Bajrami, R Marlow, M van de Ven, R Brough… - Cancer discovery, 2018 - AACR
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast
tumors. Precision medicine approaches that exploit this characteristic are not available …
tumors. Precision medicine approaches that exploit this characteristic are not available …
Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast
A Mathew, PS Rajagopal, V Villgran… - Geburtshilfe und …, 2017 - thieme-connect.com
Background Invasive lobular carcinoma (ILC) comprises around 10–15% of invasive breast
cancers. Few prior studies have demonstrated a unique pattern of metastases between ILC …
cancers. Few prior studies have demonstrated a unique pattern of metastases between ILC …
[HTML][HTML] Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism
Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast
cancer following invasive ductal carcinoma (IDC). ILC differs from IDC in a number of …
cancer following invasive ductal carcinoma (IDC). ILC differs from IDC in a number of …
Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response
Invasive lobular carcinoma (ILC) is a histologic subtype of breast cancer that is frequently
associated with favorable outcomes, as approximately 90% of ILC express the estrogen …
associated with favorable outcomes, as approximately 90% of ILC express the estrogen …
[HTML][HTML] Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer
Background Invasive lobular carcinoma (ILC) as a disease entity distinct from invasive
ductal carcinoma (IDC) has merited focused studies of the genomic landscape, but those to …
ductal carcinoma (IDC) has merited focused studies of the genomic landscape, but those to …
Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer
Background Invasive lobular breast carcinoma (ILC) is a histological subtype of breast
cancer that is characterized by loss of E-cadherin and high expression of estrogen receptor …
cancer that is characterized by loss of E-cadherin and high expression of estrogen receptor …
E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer
K Teo, L Gómez-Cuadrado, M Tenhagen, A Byron… - Scientific reports, 2018 - nature.com
Despite the fact that loss of E-cadherin is causal to the development and progression of
invasive lobular carcinoma (ILC), options to treat this major breast cancer subtype are …
invasive lobular carcinoma (ILC), options to treat this major breast cancer subtype are …
Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?
S Guiu, A Wolfer, W Jacot, P Fumoleau… - Critical reviews in …, 2014 - Elsevier
The WHO classification of breast tumors distinguishes, besides invasive breast cancer 'of no
special type'(former invasive ductal carcinoma, representing 60–70% of all breast cancers) …
special type'(former invasive ductal carcinoma, representing 60–70% of all breast cancers) …